ليتروزول تيڤع

Χώρα: Ισραήλ

Γλώσσα: Αραβικά

Πηγή: Ministry of Health

Δραστική ουσία:

LETROZOLE 2.5 MG

Διαθέσιμο από:

TEVA PHARMACEUTICAL INDUST.LTD

Φαρμακολογική κατηγορία (ATC):

L02BG04

Φαρμακοτεχνική μορφή:

TABLETS

Οδός χορήγησης:

PER OS

Κατασκευάζεται από:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Θεραπευτική ομάδα:

LETROZOLE

Θεραπευτικές ενδείξεις:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Ημερομηνία της άδειας:

2010-01-01